IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.

[1]  D. Cameron,et al.  Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. , 2015, The Lancet. Oncology.

[2]  P. Craft,et al.  Surgical margins and risk of locoregional recurrence in invasive breast cancer: an analysis of 10-year data from the Breast Cancer Treatment Quality Assurance Project. , 2013, Breast.

[3]  R. Rocha,et al.  False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma , 2013, Journal of Clinical Pathology.

[4]  Barbara L. Smith,et al.  Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R Peto,et al.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.

[6]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Cuzick,et al.  Predictive algorithms for adjuvant therapy: TransATAC , 2011, Steroids.

[8]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[9]  D. Roder,et al.  Variation in the management of early breast cancer in rural and metropolitan centres: implications for the organisation of rural cancer services. , 2010, Breast.

[10]  Hans Christian Pedersen,et al.  Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy , 2010, Breast Cancer Research.

[11]  S. Paik,et al.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Rafael Rocha,et al.  Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry. , 2008, Pathology, research and practice.

[13]  Fatima Cardoso,et al.  The MINDACT trial: The first prospective clinical validation of a genomic tool , 2007, Molecular oncology.

[14]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Gross,et al.  Effectiveness of radiation therapy for older women with early breast cancer. , 2006, Journal of the National Cancer Institute.

[16]  C. Geyer,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[18]  A. Taghian,et al.  Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Melania Pintilie,et al.  Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. , 2004, The New England journal of medicine.

[20]  Norman Wolmark,et al.  Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[23]  P. Craft,et al.  Implementing clinical practice guidelines: a community‐based audit of breast cancer treatment , 2000, The Medical journal of Australia.